These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8061846)

  • 1. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure.
    Stein G; Sierakowski B; Grass P; Haufe CC; Jansa U; Weidinger G
    Blood Press Suppl; 1994; 2():47-53. PubMed ID: 8061846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
    Haufe CC; Sierakowski B; Jansa U; Stein G
    Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of spirapril in renal impairment.
    Meredith PA; Grass P; Guitard C; Elliott HL
    Blood Press Suppl; 1994; 2():14-9. PubMed ID: 8061840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spirapril in chronic renal failure.
    Stein G; Sierakowski B; Jansa U; Haufe CC
    Blood Press Suppl; 1994; 2():54-60. PubMed ID: 8061847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spirapril: pharmacokinetic properties and drug interactions.
    Grass P; Gerbeau C; Kutz K
    Blood Press Suppl; 1994; 2():7-13. PubMed ID: 8061850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
    Danielson B; Querin S; LaRochelle P; Sultan E; Mouren M; Bryce T; Stepniewski JP; Lenfant B
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S50-9. PubMed ID: 7527102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. UK Study Group of Spirapril in Hypertension.
    Fairhurst GJ
    Blood Press Suppl; 1994; 2():77-80. PubMed ID: 8061852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.
    Bevan EG; McInnes GT; Aldigier JC; Conte JJ; Grunfeld JP; Harper SJ; Meyer BH; Pauly N; Wilkinson R
    Br J Clin Pharmacol; 1993 Feb; 35(2):128-35. PubMed ID: 8443030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets.
    Schürer M; Erb K; Junge K; Schäfer HF; Schulz HU; Amschler S; Krupp S; Hermann R
    Arzneimittelforschung; 2003; 53(6):414-9. PubMed ID: 12872612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.
    Krähenbühl S; Grass P; Surve A; Kutz K; Reichen J
    Eur J Clin Pharmacol; 1993; 45(3):247-53. PubMed ID: 8276049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.
    Noble S; Sorkin EM
    Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant administration of isradipine and spirapril prevents reduction of renal function induced by acute administration of spirapril in patients with reduced renal function.
    Wittenberg C; Erman A; Shohat J; Boner G
    Blood Press Suppl; 1994; 1():48-9. PubMed ID: 8205299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension.
    Guitard C; Alvisi V; Maibach E; Franck J; Cocco G; Boxho G; Mellein B; Waite R
    Blood Press Suppl; 1994; 2():81-7. PubMed ID: 8061853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
    Toutain PL; Lefebvre HP; Laroute V
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE-inhibitor therapy with spirapril increases nocturnal hypotensive episodes in elderly hypertensive patients.
    Kantola I; Terént A; Kataja M; Breig-Asberg E
    J Hum Hypertens; 2001 Dec; 15(12):873-8. PubMed ID: 11773991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.